Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 11/01/22
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of MedicineBusiness Wire • 10/19/22
Knight Therapeutics Announces Regulatory Submission for Tafasitamab in BrazilGlobeNewsWire • 10/06/22
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal AntibodyBusiness Wire • 10/03/22
Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable ChartSeeking Alpha • 09/29/22
Incyte (INCY) Down 2.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/01/22
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 RearrangementBusiness Wire • 08/26/22
Data from Incyte's Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) CongressBusiness Wire • 08/24/22
Incyte Posts Strong Quarter For Cancer Drug; Here's Why Shares CrumbledInvestors Business Daily • 08/02/22
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/02/22
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 08/02/22